Literature DB >> 29464499

Catechin Attenuates Coronary Heart Disease in a Rat Model by Inhibiting Inflammation.

Su Tu1, Feng Xiao2, Xiaoyan Min3, Huiping Chen4, Xiaochun Fan1, Kejiang Cao5.   

Abstract

Accumulating evidence has established that systemic inflammation is an important pathophysiologic factor of coronary heart disease (CHD). In this study, we investigated whether catechin exerts anti-inflammatory function in CHD rats. CHD model of rats was established by high-fat diet feeding and pituitrin injection. The successful building of CHD model was confirmed using blood liquid biochemical analyzer. Additionally, the effects of catechin on CHD parameters and several inflammatory signaling were investigated. The levels of total cholesterol, high-density lipoprotein, low-density lipoprotein cholesterin, triglyceride and blood glucose were all significantly elevated in CHD rats compared to them in control rats, suggesting the successful establishment of CHD model. Administration of catechin attenuated CHD by reversing the levels of creatine kinase, creatine kinase-MB, lactate dehydrogenase, cardiac troponin (cTnT), ventricular ejection fraction (LVEF) and systolic internal diameter (LVIDs). Additionally, several inflammatory biomarkers or cytokines such as C-reactive protein, lipoprotein-associated phospholipase A2 (Lp-PLA2), interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-α) were inhibited by catechin. In contrast to nuclear factor-kappa beta (NF-κB), several proteins involved in inflammation such as farnesoid X receptor, signal transducers and activators of transcription (STAT)-3 and protein kinase B (PKB/Akt) were all activated by catechin. Catechin could be used as a promising treatment for CHD based on its role in suppressing inflammation and balancing STAT-3 signaling.

Entities:  

Keywords:  Catechin; Coronary heart disease (CHD); Inflammation; Nuclear factor-kappa B (NF-κB); Signal transducers and activators of transcription (STAT)-3

Mesh:

Substances:

Year:  2018        PMID: 29464499     DOI: 10.1007/s12012-018-9449-z

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  5 in total

1.  The Therapeutic Role of Slit2 in Anti-fibrosis, Anti-inflammation and Anti-oxidative Stress in Rats with Coronary Heart Disease.

Authors:  Ji-Wei Liu; Hai-Tao Liu; Lin Chen
Journal:  Cardiovasc Toxicol       Date:  2021-08-19       Impact factor: 3.231

2.  Study on the potential mechanism of the active components in YiYiFuZi powder in homotherapy for hetropathy of coronary heart disease and rheumatoid arthritis.

Authors:  Yuming Wang; Xiaokai Li; Kun Gu; Jing Gou; Xue Li; Yaqian Dong; Rui Li; Jinxia Wei; Zhiying Dou; Yubo Li
Journal:  Front Chem       Date:  2022-08-09       Impact factor: 5.545

3.  Red Wine Grape Pomace Attenuates Atherosclerosis and Myocardial Damage and Increases Survival in Association with Improved Plasma Antioxidant Activity in a Murine Model of Lethal Ischemic Heart Disease.

Authors:  Katherine Rivera; Francisca Salas-Pérez; Guadalupe Echeverría; Inés Urquiaga; Sara Dicenta; Druso Pérez; Paula de la Cerda; Leticia González; Marcelo E Andia; Sergio Uribe; Cristián Tejos; Gonzalo Martínez; Dolores Busso; Pablo Irarrázaval; Attilio Rigotti
Journal:  Nutrients       Date:  2019-09-06       Impact factor: 5.717

4.  Neuroprotective potential of imatinib in global ischemia-reperfusion-induced cerebral injury: possible role of Janus-activated kinase 2/signal transducer and activator of transcription 3 and connexin 43.

Authors:  Jieying Wang; Taomin Bai; Nana Wang; Hongyan Li; Xiangyang Guo
Journal:  Korean J Physiol Pharmacol       Date:  2020-12-20       Impact factor: 2.016

5.  TCMIP v2.0 Powers the Identification of Chemical Constituents Available in Xinglou Chengqi Decoction and the Exploration of Pharmacological Mechanisms Acting on Stroke Complicated With Tanre Fushi Syndrome.

Authors:  Ping Wang; Shuang Wang; Hong Chen; Xiaofang Deng; Luoqi Zhang; Haiyu Xu; Hongjun Yang
Journal:  Front Pharmacol       Date:  2021-07-15       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.